Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
出版年份 2021 全文链接
标题
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
作者
关键词
-
出版物
International Journal of General Medicine
Volume Volume 14, Issue -, Pages 8557-8571
出版商
Informa UK Limited
发表日期
2021-11-23
DOI
10.2147/ijgm.s332458
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study
- (2021) Hany M. Dabbous et al. ARCHIVES OF VIROLOGY
- Favipiravir in Therapy of Viral Infections
- (2021) Ryta Łagocka et al. Journal of Clinical Medicine
- Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series
- (2021) Marc-Antoine Lepage et al. CLINICAL TOXICOLOGY
- Management of hospitalised adults with coronavirus disease-19 (COVID-19): A European Respiratory Society living guideline
- (2021) James D. Chalmers et al. EUROPEAN RESPIRATORY JOURNAL
- Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia
- (2021) Masoud Solaymani-Dodaran et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses
- (2021) Nicola Borbone et al. MOLECULES
- Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials
- (2021) Chih-Cheng Lai et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis
- (2021) Mohammad Tasavon Gholamhoseini et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial
- (2021) Hany M. Dabbous et al. Scientific Reports
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19
- (2021) Gilmar Reis et al. JAMA Network Open
- Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
- (2021) Toshie Manabe et al. BMC INFECTIOUS DISEASES
- Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARS-CoV-2 Infection
- (2021) Michele Costanzo et al. CURRENT MEDICINAL CHEMISTRY
- Effectiveness of favipiravir in COVID-19: a live systematic review
- (2021) Batu Özlüşen et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis
- (2021) Surjit Singh et al. BMJ Open
- Pharmacological Effects of Favipiravir on Coronavirus: An Update
- (2021) Prerna Tejaswi et al. Biomedical and Pharmacology Journal
- Connecting With Patients—The Missing Links
- (2020) Lisa Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Coronavirus Infections—More Than Just the Common Cold
- (2020) Catharine I. Paules et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Remdesivir in Treatment of COVID-19: A Systematic Benefit–Risk Assessment
- (2020) Miranda Davies et al. DRUG SAFETY
- COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal
- (2020) Hasan K. Siddiqi et al. JOURNAL OF HEART AND LUNG TRANSPLANTATION
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
- (2020) Yeming Wang et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
- (2020) Bin Cao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
- (2020) Qingxian Cai et al. Engineering
- A prospect on the use of antiviral drugs to control local outbreaks of COVID-19
- (2020) Andrea Torneri et al. BMC Medicine
- Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
- (2020) Hong Zhao et al. BIOMEDICINE & PHARMACOTHERAPY
- Web tools to fight pandemics: the COVID-19 experience
- (2020) Daniele Mercatelli et al. BRIEFINGS IN BIOINFORMATICS
- Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial
- (2020) Yan Lou et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
- (2020) Peter W Horby et al. LANCET
- COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment
- (2020) Anant Parasher POSTGRADUATE MEDICAL JOURNAL
- Characteristics and outcomes of acute respiratory distress syndrome related to COVID-19 in Belgian and French intensive care units according to antiviral strategies: the COVADIS multicentre observational study
- (2020) David Grimaldi et al. Annals of Intensive Care
- COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine
- (2020) Wenyi Guan et al. VIROLOGICA SINICA
- Detailed Molecular Interactions of Favipiravir with SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza Virus Polymerases In Silico
- (2020) Mitsuru Sada et al. Microorganisms
- Efficacy and safety of lopinavir/ritonavir in the treatment of COVID-19: A systematic review
- (2020) Betsy Ann Joseph et al. Expert Review of Anti-Infective Therapy
- Role of favipiravir in the treatment of COVID-19
- (2020) Shashank Joshi et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia
- (2020) Faryal Khamis et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
- (2020) Andre C. Kalil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis
- (2020) Alejandro Piscoya et al. PLoS One
- Antimicrobial Peptide K11 Selectively Recognizes Bacterial Biomimetic Membranes and Acts by Twisting Their Bilayers
- (2020) Francisco Ramos-Martín et al. Pharmaceuticals
- Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
- (2020) Zarir F. Udwadia et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Coronaviruses — drug discovery and therapeutic options
- (2016) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started